Teva Pharmaceutical Industries (NYSE:TEVA) Price Target Raised to $57.00

Teva Pharmaceutical Industries (NYSE:TEVA) had its target price raised by TD Cowen from $55.00 to $57.00 in a research note released on Wednesday,Benzinga reports. They currently have a buy rating on the stock.

Other analysts also recently issued reports about the company. UBS Group lifted their price objective on Teva Pharmaceutical Industries from $42.00 to $48.00 and gave the company a “buy” rating in a report on Friday, September 4th. Leerink Partners assumed coverage on Teva Pharmaceutical Industries in a report on Wednesday, September 9th. They set an “outperform” rating and a $45.00 target price for the company. Zacks Research cut Teva Pharmaceutical Industries from a “hold” rating to a “strong sell” rating in a research report on Tuesday, October 20th. Barclays lifted their price target on Teva Pharmaceutical Industries from $42.00 to $47.00 and gave the company an “overweight” rating in a report on Thursday, October 15th. Finally, Oppenheimer boosted their price target on Teva Pharmaceutical Industries from $50.00 to $52.00 and gave the stock an “outperform” rating in a research report on Friday, October 9th. Thirteen analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, Teva Pharmaceutical Industries presently has a consensus rating of “Moderate Buy” and an average price target of $47.23.

Teva Pharmaceutical Industries Trading Up 1.8%

TEVA traded up $0.74 during trading on Wednesday, hitting $42.52. 6,191,016 shares of the stock were exchanged, compared to its average volume of 6,600,758. The firm has a 50 day simple moving average of $39.49 and a 200 day simple moving average of $34.79. The firm has a market cap of $49.55 billion, a price-to-earnings ratio of 98.88, a P/E/G ratio of 3.77 and a beta of 0.97. Teva Pharmaceutical Industries has a 1 year low of $23.61 and a 1 year high of $43.34. The company has a debt-to-equity ratio of 1.56, a quick ratio of 0.67 and a current ratio of 0.88.

Teva Pharmaceutical Industries (NYSE:TEVA) last issued its earnings results on Tuesday, November 3rd. The company reported $0.86 earnings per share for the quarter, topping the consensus estimate of $0.72 by $0.14. Teva Pharmaceutical Industries had a return on equity of 32.64% and a net margin of 4.08%. The business had revenue of $4.39 billion during the quarter, compared to analysts’ expectations of $4.23 billion. During the same period in the prior year, the business earned $0.78 EPS. The business’s revenue for the quarter was down 1.9% compared to the same quarter last year. As a group, equities analysts expect that Teva Pharmaceutical Industries will post 1.98 EPS for the current year.

Insider Buying and Selling at Teva Pharmaceutical Industries

In other Teva Pharmaceutical Industries news, insider Mark Sabag sold 46,000 shares of Teva Pharmaceutical Industries stock in a transaction on Thursday, November 5th. The shares were sold at an average price of $41.93, for a total value of $1,928,780.00. Following the transaction, the insider directly owned 80,760 shares of the company’s stock, valued at approximately $3,386,266.80. The trade was a 36.29% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Brian Savage sold 7,342 shares of Teva Pharmaceutical Industries stock in a transaction on Friday, September 18th. The stock was sold at an average price of $38.85, for a total transaction of $285,236.70. Following the completion of the transaction, the insider directly owned 8,500 shares in the company, valued at $330,225. This represents a 46.35% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold a total of 420,942 shares of company stock worth $16,572,473 over the last three months. Corporate insiders own 0.54% of the company’s stock.

Institutional Trading of Teva Pharmaceutical Industries

Institutional investors have recently made changes to their positions in the business. Root Financial Partners LLC acquired a new position in Teva Pharmaceutical Industries during the 3rd quarter valued at about $33,000. Cornerstone Planning Group LLC boosted its holdings in Teva Pharmaceutical Industries by 547.1% in the first quarter. Cornerstone Planning Group LLC now owns 893 shares of the company’s stock worth $27,000 after acquiring an additional 755 shares in the last quarter. Western Wealth Management LLC purchased a new stake in shares of Teva Pharmaceutical Industries during the first quarter worth about $43,000. Sunbelt Securities Inc. purchased a new stake in shares of Teva Pharmaceutical Industries during the first quarter worth about $45,000. Finally, CX Institutional purchased a new stake in shares of Teva Pharmaceutical Industries during the second quarter worth about $54,000. Institutional investors and hedge funds own 54.05% of the company’s stock.

Teva Pharmaceutical Industries News Roundup

Here are the key news stories impacting Teva Pharmaceutical Industries this week:

• Positive Sentiment: Teva’s third-quarter earnings beat estimates, and the company raised its 2026 revenue and product-sales outlook, citing strong branded-drug sales. Revenue was slightly lower year over year, but the results and upgraded outlook were encouraging. Article: Teva Q3 Earnings Beat Estimates, 2026 Revenue View Raised, Stock Up
• Positive Sentiment: A report highlighted 33% sales growth last quarter across Teva’s three key branded medicines, alongside improved margins and net-debt reduction—factors that could strengthen earnings and the balance sheet. Article: Teva’s 3 Key Branded Drugs Grew Sales 33% Last Quarter
• Positive Sentiment: Leerink Partners raised its price target to $52 from $45 and maintained an “outperform” rating, signaling greater analyst confidence in potential upside. Article: Leerink Partners Raises Teva Price Target
• Positive Sentiment: HC Wainwright reiterated a “Buy” rating with a $52 target and projected 2027 EPS of $3.03, well above its 2026 estimate of $1.94. Teva analyst estimates
• Negative Sentiment: Insider Mark Sabag sold 46,000 shares for about $1.93 million, reducing his direct holdings by 36.29%. Insider sales can weigh on sentiment, though they do not necessarily indicate a change in the company’s outlook. SEC insider transaction filing

Teva Pharmaceutical Industries Company Profile

Teva Pharmaceutical Industries is a global pharmaceutical company that develops, manufactures and markets generic medicines, specialty medicines and biosimilars. Its portfolio spans treatments for conditions including neurological disorders, respiratory diseases and cancer, alongside a broad range of generic medicines across therapeutic areas.

Founded in Jerusalem in 1901, Teva has grown from a regional pharmaceutical business into an international company. It serves patients and healthcare providers in markets around the world, including North America, Europe and other regions.

Teva is headquartered in Tel Aviv, Israel.